We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 315.00 | 310.00 | 320.00 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 315.00 | 315.00 | 315.00 | 202 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -10.62 | 402.63M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/4/2024 | 13:05 | UK RNS | MaxCyte, Inc. Notice of Results |
| 03/4/2024 | 07:00 | UK RNS | MaxCyte, Inc. Total Voting Rights and Block Listing Return |
| 02/4/2024 | 15:19 | ALNC |  TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout |
| 02/4/2024 | 13:05 | UK RNS | MaxCyte, Inc. Signing of Strategic Platform License |
| 02/4/2024 | 07:00 | UK RNS | MaxCyte, Inc. Exercise of options and PDMR dealing |
| 20/3/2024 | 10:16 | UK RNS | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing |
| 20/3/2024 | 10:05 | UK RNS | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing |
| 13/3/2024 | 11:54 | ALNC | IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25% |
| 13/3/2024 | 07:05 | UK RNS | MaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023 |
| 13/3/2024 | 07:00 | UK RNS | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results |
1 Year Maxcyte Chart |
Intraday Maxcyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
